WM
MCID: LYM012
MIFTS: 61

Lymphoplasmacytic Lymphoma (WM)

Categories: Blood diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma 12 52 36 15 37
Waldenstrom Macroglobulinemia 12 52 25 58 29 54 43 39 17 71
Macroglobulinemia of Waldenstrom 52 25
Malignant Lymphoma - Lymphoplasmacytic 71
Waldenstrom's Macroglobulinaemia 52
Waldenström's Macroglobulinemia 74
Waldenstrom's Macroglobulinemia 25
Waldenström Macroglobulinemia 25
Waldenstrom's Syndrome 52
Wm 25

Characteristics:

Orphanet epidemiological data:

58
waldenstrom macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Lymphoplasmacytic Lymphoma

Genetics Home Reference : 25 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma. The abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and of more mature cells derived from B cells known as plasma cells. These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia"). Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer. Some affected individuals have elevated levels of IgM and lymphoplasmacytic cells but no symptoms of the condition; in these cases, the disease is usually found incidentally by a blood test taken for another reason. These individuals are diagnosed with smoldering (or asymptomatic) Waldenström macroglobulinemia. It can be several years before this form of the condition progresses to the symptomatic form. Individuals with symptomatic Waldenström macroglobulinemia can experience general symptoms such as fever, night sweats, and weight loss. Several other signs and symptoms of the condition are related to the excess IgM, which can thicken blood and impair circulation, causing a condition known as hyperviscosity syndrome. Features related to hyperviscosity syndrome include bleeding in the nose or mouth, blurring or loss of vision, headache, dizziness, and difficulty coordinating movements (ataxia). In some affected individuals, the IgM proteins clump together in the hands and feet, where the body temperature is cooler than at the center of the body. These proteins are then referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures. The IgM protein can also build up in organs such as the heart and kidneys, causing a condition called amyloidosis, which can lead to heart and kidney problems. Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy). Doctors are unsure why this feature occurs, although they speculate that the IgM protein attaches to the protective covering of nerve cells (myelin) and breaks it down. The damaged nerves cannot carry signals normally, leading to neuropathy. Other features of Waldenström macroglobulinemia are due to the accumulation of lymphoplasmacytic cells in different tissues. For example, accumulation of these cells can lead to an enlarged liver (hepatomegaly), spleen (splenomegaly), or lymph nodes (lymphadenopathy). In the bone marrow, the lymphoplasmacytic cells interfere with normal blood cell development, causing a shortage of normal blood cells (pancytopenia). Excessive tiredness (fatigue) due to a reduction in red blood cells (anemia) is common in affected individuals. People with Waldenström macroglobulinemia have an increased risk of developing other cancers of the blood or other tissues.

MalaCards based summary : Lymphoplasmacytic Lymphoma, also known as waldenstrom macroglobulinemia, is related to waldenstroem's macroglobulinemia and macroglobulinemia. An important gene associated with Lymphoplasmacytic Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Lenograstim and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are leukemia and lymphoma

Disease Ontology : 12 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

NIH Rare Diseases : 52 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder . It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy , fever, Raynaud's phenomenon , and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition . Treatment is often reserved for those with symptoms and may include various medications including corticosteroids , alkylating agents , biologic response modifiers and purine analogues.

KEGG : 36 Lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL) subtype characterized by small B-lymphocytes, plasmacytoid lymphocytes, and plasma cells, usually involving bone marrow, lymph nodes, and the spleen. WM can be distinguished clinically from LPL on the basis of a detectable monoclonal (IgM) immunoglobulin spike in serum. In the general population, LPL/WM is a very rare disease, accounting for only 1%-2% of all hematologic malignancies, reflected in an incidence rate of 3-4 cases per million people per year. The t(9;14)(p13;q32) is present in near 50% of cases of LPL. This chromosomal translocation involves a junction between 9p13 and the switch micro region of the Ig heavy chain locus on 14q32. The 9p13 breakpoint contains the PAX-5 gene which encodes a B-cell specific transcription factor involved in the control of B-cell proliferation and differentiation. The translocation causes the juxtaposition of the PAX-5 gene to the IgH locus in the opposite direction of transcription, resulting in an 11-fold over-expression of PAX-5 mRNA.

Wikipedia : 74 Waldenstrom's macroglobulinemia (WM), is a type of cancer affecting two types of B cells:... more...

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 499, show less)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 34.0 MYD88 MAG CXCR4 CD40LG
2 macroglobulinemia 31.9 PAX5 MYD88 CXCR4 CXCL12 CD40LG
3 lymphoma 31.6 PAX5 MYD88 MS4A1 IRF4 CXCR4 CD40LG
4 marginal zone b-cell lymphoma 31.2 PAX5 MYD88 IRF4 CD40LG CCND1
5 diffuse large b-cell lymphoma 31.0 PAX5 MYD88 MIR155 IRF4 CCND1
6 mononeuritis multiplex 31.0 MAG CD40LG
7 gamma heavy chain disease 31.0 MYD88 CD40LG
8 heavy chain disease 31.0 MYD88 CD40LG
9 whim syndrome 31.0 CXCR4 CXCL12 ACKR3
10 lymphoma, hodgkin, classic 30.9 PAX5 MS4A1 MIR155 IRF4
11 monoclonal paraproteinemia 30.9 PAX5 CD40LG
12 cll/sll 30.9 ZAP70 PAX5 CCND1
13 agammaglobulinemia, x-linked 30.8 CXCR4 CXCL12 CD40LG
14 leukemia, acute myeloid 30.8 PAX5 MIR184 MIR155 CXCR4 CXCL12 CCND1
15 combined t cell and b cell immunodeficiency 30.7 ZAP70 IRF4 CD40LG
16 central nervous system lymphoma 30.7 PAX5 MYD88 CXCR4 CXCL12
17 plasmacytoma 30.7 PAX5 IRF4 IGH CXCL12 CCND1
18 lymphocytic leukemia 30.7 ZAP70 PAX5 MYD88 MS4A1 MIR155 CD40LG
19 b-cell lymphoma 30.7 ZAP70 PAX5 MYD88 MS4A1 MIR155 IRF4
20 polyradiculoneuropathy 30.7 MAG CXCR4 CXCL12 CD40LG
21 plasma cell leukemia 30.6 IRF4 CCND1
22 myeloma, multiple 30.6 PAX5 MIR155 IRF4 CXCR4 CXCL12 CD40LG
23 peripheral t-cell lymphoma 30.6 PAX5 MS4A1 CXCR4 CCND1
24 prolymphocytic leukemia 30.5 ZAP70 MS4A1 CCND1
25 follicular lymphoma 30.5 PAX5 MS4A1 MIR155 IRF4 IGH CCND1
26 monoclonal gammopathy of uncertain significance 30.4 MYD88 MAG CD40LG CCND1
27 extramedullary plasmacytoma 30.4 IRF4 CCND1
28 severe combined immunodeficiency 30.3 ZAP70 IRF4 CXCR4 CXCL12
29 lymphoma, mucosa-associated lymphoid type 30.3 ZAP70 PAX5 MYD88 IRF4 IGH CD40LG
30 mature b-cell neoplasm 30.3 PAX5 MIR155 IRF4 CD40LG CCND1
31 burkitt lymphoma 30.2 PAX5 MS4A1 MIR155 IRF4 CD40LG CCND1
32 lymphoma, non-hodgkin, familial 30.2 PAX5 MS4A1 MIR155 IRF4 IGH CXCR4
33 leukemia, chronic lymphocytic 30.0 ZAP70 PAX5 MYD88 MS4A1 MIR155 IRF4
34 leukemia, acute lymphoblastic 30.0 ZAP70 PAX5 MIR155 IRF4 IGH CXCR4
35 systemic lupus erythematosus 29.9 MYD88 MIR494 MIR184 MIR155 IRF4 CXCL12
36 mantle cell lymphoma 29.9 PAX5 MS4A1 MIR155 IGH CXCR4 CXCL12
37 lymphoplasmacytic lymphoma without igm production 12.4
38 weill-marchesani syndrome 12.0
39 macroglobulinemia, waldenstrom 1 11.9
40 tibia, hypoplasia or aplasia of, with polydactyly 11.5
41 williams-beuren syndrome 11.5
42 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 11.2
43 weill-marchesani syndrome 2 11.2
44 weill-marchesani syndrome 3 11.2
45 nodular lymphocyte predominant hodgkin lymphoma 10.6 PAX5 CCND1
46 intraocular lymphoma 10.6 PAX5 CXCR4 CXCL12
47 osteosclerotic myeloma 10.6 MAG CD40LG
48 primary cutaneous diffuse large b-cell lymphoma, leg type 10.6 MYD88 IRF4
49 aids dementia complex 10.6 CXCR4 CXCL12
50 selective igg deficiency disease 10.6 PAX5 IRF4
51 spastic monoplegia 10.5 HAS1 CD40LG
52 chronic polyneuropathy 10.5 MAG CD40LG
53 lung lymphoma 10.5 PAX5 IRF4
54 central nervous system hematologic cancer 10.5 PAX5 MYD88 IRF4
55 leukemia 10.5
56 transient arthritis 10.5 ZAP70 CD40LG
57 lymphatic system cancer 10.5 PAX5 IRF4 CD40LG
58 plasma protein metabolism disease 10.5 MYD88 MAG CXCR4 CD40LG
59 b cell prolymphocytic leukemia 10.5 ZAP70 MS4A1
60 mononeuritis of upper limb and mononeuritis multiplex 10.5 MAG CD40LG
61 primary bacterial infectious disease 10.5 MYD88 MIR155 CD40LG
62 primary central nervous system lymphoma 10.4 PAX5 MYD88
63 leukemia, chronic lymphocytic 2 10.4 ZAP70 MS4A1
64 primary cutaneous b-cell lymphoma 10.4 PAX5 MS4A1
65 temporal lobe epilepsy 10.4
66 traumatic brain injury 10.4
67 myeloid leukemia 10.4
68 autoimmune disease of central nervous system 10.4 MIR155 MAG CD40LG
69 testicular lymphoma 10.3 MYD88 IRF4
70 leukocyte disease 10.3 MIR155 IRF4 CD40LG CCND1
71 splenomegaly 10.3
72 sarcoma 10.3
73 acute leukemia 10.3
74 spindle cell sarcoma 10.3
75 autoimmune neuropathy 10.3 MAG CD40LG
76 bone marrow cancer 10.3 MIR155 IRF4 CXCR4 CD40LG CCND1
77 clear cell renal cell carcinoma 10.3 MIR494 MIR155 CXCR4 CCND1
78 mental retardation, autosomal dominant 40 10.2 CXCR4 CXCL12
79 retinal detachment 10.2
80 immune deficiency disease 10.2 ZAP70 IRF4 CXCR4 CXCL12 CD40LG
81 ocular motor apraxia 10.2
82 membranous nephropathy 10.2
83 sensory peripheral neuropathy 10.2
84 lymphopenia 10.2
85 amyloid neuropathy 10.2
86 common variable immunodeficiency 10.2 ZAP70 MS4A1 IRF4 CD40LG
87 lymphoproliferative syndrome 10.2
88 pancytopenia 10.2
89 histiocytosis 10.2
90 amyloidosis 10.2
91 brain injury 10.2
92 tetanus 10.2
93 diphtheria 10.2
94 facial paralysis 10.2
95 constipation 10.2
96 ischemia 10.2
97 brain cancer 10.2
98 squamous cell carcinoma, head and neck 10.2 MIR494 MIR155 CXCR4 CXCL12 CCND1
99 hepatocellular carcinoma 10.1
100 sarcoidosis 1 10.1
101 reticulum cell sarcoma 10.1
102 exanthem 10.1
103 portal hypertension 10.1
104 cauda equina syndrome 10.1
105 acute kidney tubular necrosis 10.1
106 pure red-cell aplasia 10.1
107 polyclonal hypergammaglobulinemia 10.1
108 interstitial lung disease 10.1
109 macular retinal edema 10.1
110 proliferative glomerulonephritis 10.1
111 chronic inflammatory demyelinating polyradiculoneuropathy 10.1
112 demyelinating polyneuropathy 10.1
113 chronic kidney disease 10.1
114 retinal degeneration 10.1
115 lung disease 10.1
116 amyloidosis aa 10.1
117 tremor 10.1
118 thrombotic microangiopathy 10.1
119 red cell aplasia 10.1
120 graft-versus-host disease 10.1
121 thrombocytopenia 10.1
122 cryoglobulinemia 10.1
123 cold agglutinin disease 10.1
124 kaposi sarcoma 10.1
125 heart disease 10.1
126 acromegaly 10.1
127 antiphospholipid syndrome 10.1
128 amnestic disorder 10.1
129 substance abuse 10.1
130 head injury 10.1
131 dowling-degos disease 1 10.1
132 myasthenia gravis 10.1
133 myelofibrosis 10.1
134 macroglobulinemia, waldenstrom 2 10.1
135 cyanosis, transient neonatal 10.1
136 myelodysplastic syndrome 10.1
137 stomatin-like protein-2, hyperphosphorylation of 10.1
138 pulmonary hypertension 10.1
139 vitamin b12 deficiency 10.1
140 colitis 10.1
141 viral pneumonia 10.1
142 protein-losing enteropathy 10.1
143 primary biliary cirrhosis 10.1
144 poems syndrome 10.1
145 retinal vein occlusion 10.1
146 optic nerve disease 10.1
147 maxillary sinusitis 10.1
148 central retinal vein occlusion 10.1
149 transitional cell carcinoma 10.1
150 hairy cell leukemia 10.1
151 purpura 10.1
152 skin disease 10.1
153 hypertrichosis 10.1
154 schnitzler syndrome 10.1
155 pustulosis of palm and sole 10.1
156 liver cirrhosis 10.1
157 central nervous system vasculitis 10.1
158 localized scleroderma 10.1
159 psoriasis 10.1
160 scotoma 10.1
161 stomatitis 10.1
162 hypotropia 10.1
163 orbit lymphoma 10.1
164 chromosome 6q deletion 10.1
165 lymphangiectasis 10.1
166 orbital lymphoma 10.1
167 eosinophilic colitis 10.1
168 miller fisher syndrome 10.0 MAG CD40LG
169 anemia, autoimmune hemolytic 10.0
170 aplastic anemia 10.0
171 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.0
172 splenic marginal zone lymphoma 10.0
173 nodal marginal zone lymphoma 10.0
174 acquired von willebrand syndrome 10.0
175 respiratory failure 10.0
176 nephrotic syndrome 10.0
177 diarrhea 10.0
178 polyneuropathy 10.0
179 richter's syndrome 10.0
180 hepatitis c 10.0
181 agammaglobulinemia 10.0
182 hemolytic anemia 10.0
183 bone lymphoma 10.0
184 thyroiditis 10.0
185 herpes zoster 10.0
186 chromosomal triplication 10.0
187 indolent b cell lymphoma 10.0
188 headache 10.0
189 muir-torre syndrome 10.0
190 pulmonary hemosiderosis 10.0
191 small cell cancer of the lung 10.0
192 lung cancer 10.0
193 secretory component deficiency 10.0
194 thrombocytopenia 1 10.0
195 leukemia, chronic myeloid 10.0
196 small cell carcinoma 10.0
197 immunoglobulin alpha deficiency 10.0
198 aphasia 10.0
199 apraxia 10.0
200 bone disease 10.0
201 cryptococcal meningitis 10.0
202 sensorineural hearing loss 10.0
203 mumps 10.0
204 hemopericardium 10.0
205 autonomic neuropathy 10.0
206 pericardial effusion 10.0
207 visual epilepsy 10.0
208 aseptic meningitis 10.0
209 dysentery 10.0
210 scleritis 10.0
211 personality disorder 10.0
212 rheumatic fever 10.0
213 impotence 10.0
214 motor peripheral neuropathy 10.0
215 mammary paget's disease 10.0
216 systemic mastocytosis 10.0
217 thrombophlebitis 10.0
218 lynch syndrome 10.0
219 sebaceous adenocarcinoma 10.0
220 pancreatitis 10.0
221 cerebral lymphoma 10.0
222 silent myocardial infarction 10.0
223 acquired immunodeficiency syndrome 10.0
224 adenoma 10.0
225 hyperthyroidism 10.0
226 septic arthritis 10.0
227 measles 10.0
228 chickenpox 10.0
229 myeloid sarcoma 10.0
230 rubella 10.0
231 diabetes insipidus 10.0
232 haemophilus influenzae 10.0
233 seizure disorder 10.0
234 osteonecrosis of the jaw 10.0
235 nodal marginal zone b-cell lymphoma 10.0
236 amyloidosis, hereditary, transthyretin-related 10.0
237 fanconi renotubular syndrome 1 10.0
238 stiff-person syndrome 10.0
239 celiac disease 1 10.0
240 factor x deficiency 10.0
241 autoimmune lymphoproliferative syndrome, type v 10.0
242 hydrops, lactic acidosis, and sideroblastic anemia 10.0
243 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
244 angiosarcoma 10.0
245 autoimmune peripheral neuropathy 10.0
246 cryptogenic organizing pneumonia 10.0
247 atrial fibrillation 10.0
248 cardiac arrest 10.0
249 mucositis 10.0
250 osteonecrosis 10.0
251 osteomyelitis 10.0
252 fanconi syndrome 10.0
253 gastric ulcer 10.0
254 optic neuritis 10.0
255 angioedema 10.0
256 pneumothorax 10.0
257 iron metabolism disease 10.0
258 nonspecific interstitial pneumonia 10.0
259 scleredema adultorum 10.0
260 progressive multifocal leukoencephalopathy 10.0
261 muscular atrophy 10.0
262 meningitis 10.0
263 bronchiectasis 10.0
264 acquired angioedema 10.0
265 blastic plasmacytoid dendritic cell 10.0
266 chronic graft versus host disease 10.0
267 cytokine deficiency 10.0
268 dendritic cell tumor 10.0
269 granulocytopenia 10.0
270 light chain deposition disease 10.0
271 lymphosarcoma 10.0
272 polymyositis 10.0
273 t-cell lymphoma 1a 10.0
274 back pain 10.0
275 dysphagia 10.0
276 hypoxia 10.0
277 syncope 10.0
278 partial deletion of the long arm of chromosome 6 10.0
279 muscular tumor 10.0
280 pneumococcal meningitis 10.0
281 type ii mixed cryoglobulinemia 10.0
282 thyroid carcinoma 10.0
283 amyotrophic lateral sclerosis 1 10.0
284 complement component 4, partial deficiency of 10.0
285 multiple sclerosis 10.0
286 leukemia, acute monocytic 10.0
287 myositis 10.0
288 ovarian cancer 10.0
289 pernicious anemia 10.0
290 thrombocytopenic purpura, autoimmune 10.0
291 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.0
292 mycosis fungoides 10.0
293 osteogenic sarcoma 10.0
294 ectodermal dysplasia and immunodeficiency 1 10.0
295 kearns-sayre syndrome 10.0
296 branchiootic syndrome 1 10.0
297 birdshot chorioretinopathy 10.0
298 meningioma, radiation-induced 10.0
299 meningioma, familial 10.0
300 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
301 thrombocytopenia 4 10.0
302 gastric cancer 10.0
303 human herpesvirus 8 10.0
304 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
305 angina pectoris 10.0
306 anaplastic large cell lymphoma 10.0
307 c1 inhibitor deficiency 10.0
308 cutaneous t cell lymphoma 10.0
309 autosomal recessive pyridoxine-refractory sideroblastic anemia 2 10.0
310 visual agnosia 10.0
311 ptosis 10.0
312 fibrogenesis imperfecta ossium 10.0
313 angioimmunoblastic t-cell lymphoma 10.0
314 pleurisy 10.0
315 bacterial infectious disease 10.0
316 lipoid nephrosis 10.0
317 spinal meningioma 10.0
318 mononeuropathy 10.0
319 retinal ischemia 10.0
320 crescentic glomerulonephritis 10.0
321 gout 10.0
322 pulmonary sarcoidosis 10.0
323 hypothyroidism 10.0
324 urticaria 10.0
325 alcohol use disorder 10.0
326 rheumatic disease 10.0
327 thrombocytopenia due to platelet alloimmunization 10.0
328 neuritis 10.0
329 cholecystitis 10.0
330 enthesopathy 10.0
331 hepatitis b 10.0
332 hepatitis 10.0
333 lateral sclerosis 10.0
334 motor neuron disease 10.0
335 gastroenteritis 10.0
336 hypersensitivity reaction type iv disease 10.0
337 pulmonary tuberculosis 10.0
338 glioblastoma multiforme 10.0
339 hyperglobulinemic purpura 10.0
340 cellulitis 10.0
341 arthropathy 10.0
342 cranial nerve palsy 10.0
343 agnosia 10.0
344 syphilis 10.0
345 polyradiculopathy 10.0
346 neuromuscular disease 10.0
347 secretory meningioma 10.0
348 lymphoplasmacyte-rich meningioma 10.0
349 uremia 10.0
350 rapidly progressive glomerulonephritis 10.0
351 prosopagnosia 10.0
352 congestive heart failure 10.0
353 axonal neuropathy 10.0
354 intestinal obstruction 10.0
355 ileus 10.0
356 paralytic ileus 10.0
357 arthritis 10.0
358 monocytic leukemia 10.0
359 herpes simplex 10.0
360 megakaryocytic leukemia 10.0
361 lupus erythematosus 10.0
362 rosacea 10.0
363 gas gangrene 10.0
364 pemphigus 10.0
365 intracranial hypertension 10.0
366 encephalitis 10.0
367 miliary tuberculosis 10.0
368 alopecia 10.0
369 toxoplasmosis 10.0
370 48,xyyy 10.0
371 acute monoblastic leukemia 10.0
372 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.0
373 cryofibrinogenemia 10.0
374 grover's disease 10.0
375 limbic encephalitis 10.0
376 lymphomatoid papulosis 10.0
377 marek disease 10.0
378 myeloid splenomegaly 10.0
379 nodular regenerative hyperplasia 10.0
380 primary agammaglobulinemia 10.0
381 pure autonomic failure 10.0
382 xanthoma disseminatum 10.0
383 encephalopathy 10.0
384 fainting 10.0
385 paraneoplastic syndromes 10.0
386 paresthesia 10.0
387 posttransplant acute limbic encephalitis 10.0
388 monosomy 21 10.0
389 argyria 10.0
390 autoimmune hemolytic anemia, warm type 10.0
391 plasma cell tumor 10.0
392 overgrowth syndrome 10.0
393 hypohidrotic ectodermal dysplasia with immunodeficiency 10.0
394 refractory anemia 10.0
395 exudative vitreoretinopathy 1 10.0
396 huntington disease 10.0
397 renal cell carcinoma, nonpapillary 10.0
398 polydactyly, preaxial ii 10.0
399 strabismus 10.0
400 syndactyly, type iv 10.0
401 autism 10.0
402 wilson disease 10.0
403 aging 10.0
404 dysphasia, familial developmental 10.0
405 frontotemporal dementia 10.0
406 polydactyly 10.0
407 polysubstance abuse 10.0
408 anxiety 10.0
409 specific language impairment 10.0
410 lyme disease 10.0
411 epilepsy 10.0
412 relapsing-remitting multiple sclerosis 10.0
413 dyslexia 10.0
414 compartment syndrome 10.0
415 vascular dementia 10.0
416 learning disability 10.0
417 mechanical strabismus 10.0
418 autoimmune disease 9.9
419 cardiac arrhythmia 9.9
420 cryoglobulinemia, familial mixed 9.9
421 hashimoto thyroiditis 9.9
422 neurofibromatosis, type iv, of riccardi 9.9
423 scleroderma, familial progressive 9.9
424 temporal arteritis 9.9
425 thrombophilia due to thrombin defect 9.9
426 gaucher disease, type i 9.9
427 polycythemia vera 9.9
428 wiskott-aldrich syndrome 9.9
429 retinitis pigmentosa 11 9.9
430 yemenite deaf-blind hypopigmentation syndrome 9.9
431 allergic rhinitis 9.9
432 hepatitis c virus 9.9
433 deficiency anemia 9.9
434 paroxysmal nocturnal hemoglobinuria 9.9
435 pollen allergy 9.9
436 thrombosis 9.9
437 castleman disease 9.9
438 gastric lymphoma 9.9
439 disseminated intravascular coagulation 9.9
440 pyelonephritis 9.9
441 hemosiderosis 9.9
442 goiter 9.9
443 neutropenia 9.9
444 von willebrand's disease 9.9
445 guillain-barre syndrome 9.9
446 acute cystitis 9.9
447 toxic shock syndrome 9.9
448 renal tubular acidosis 9.9
449 prostatitis 9.9
450 nodular nonsuppurative panniculitis 9.9
451 gaucher's disease 9.9
452 pharyngitis 9.9
453 nocardiosis 9.9
454 membranoproliferative glomerulonephritis 9.9
455 glomerulonephritis 9.9
456 iga glomerulonephritis 9.9
457 acute kidney failure 9.9
458 gingivitis 9.9
459 liposarcoma 9.9
460 mastocytosis 9.9
461 lactic acidosis 9.9
462 liver disease 9.9
463 myopathy 9.9
464 hepatitis e 9.9
465 kidney disease 9.9
466 peripheral nervous system disease 9.9
467 hemoglobinuria 9.9
468 composite lymphoma 9.9
469 bronchitis 9.9
470 hypersplenism 9.9
471 periodontitis 9.9
472 polycythemia 9.9
473 collagen disease 9.9
474 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.9
475 vasculitis 9.9
476 neuropathy 9.9
477 evans' syndrome 9.9
478 gastrointestinal lymphoma 9.9
479 peliosis hepatis 9.9
480 hard palate cancer 9.9
481 exophthalmos 9.9
482 smoldering myeloma 9.9
483 polyarteritis nodosa 9.9
484 hypereosinophilic syndrome 9.9
485 hypoglycemia 9.9
486 47,xyy 9.9
487 acute graft versus host disease 9.9
488 al amyloidosis 9.9
489 distal renal tubular acidosis 9.9
490 immunotactoid glomerulopathy 9.9
491 necrobiotic xanthogranuloma 9.9
492 b-cell non-hodgkin lymphoma 9.9
493 acute sensory ataxic neuropathy 9.9
494 primary bone lymphoma 9.9
495 indolent b-cell non-hodgkin lymphoma 9.9
496 ah amyloidosis 9.9
497 cancer-associated retinopathy 9.9
498 intravascular large b-cell lymphoma 9.9
499 hematologic cancer 9.8 ZAP70 PAX5 MIR542 MIR155 IRF4 CXCR4

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:



Diseases related to Lymphoplasmacytic Lymphoma

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

Human phenotypes related to Lymphoplasmacytic Lymphoma:

58 31 (showing 47, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001909
2 lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002665
3 monoclonal immunoglobulin m proteinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0005508
4 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
5 hypercoagulability 58 31 frequent (33%) Frequent (79-30%) HP:0100724
6 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
7 gingival bleeding 58 31 frequent (33%) Frequent (79-30%) HP:0000225
8 vertigo 58 31 frequent (33%) Frequent (79-30%) HP:0002321
9 abnormality of neutrophils 58 31 frequent (33%) Frequent (79-30%) HP:0001874
10 normocytic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001897
11 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
12 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
13 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
14 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
15 malabsorption 58 31 occasional (7.5%) Occasional (29-5%) HP:0002024
16 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
17 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
18 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
19 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
20 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
21 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
22 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
23 urticaria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001025
24 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
25 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
26 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
27 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
28 migraine 58 31 occasional (7.5%) Occasional (29-5%) HP:0002076
29 proptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000520
30 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
31 recurrent infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0002719
32 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
33 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
34 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
35 stroke 58 31 occasional (7.5%) Occasional (29-5%) HP:0001297
36 periorbital edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100539
37 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
38 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
39 retinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0000573
40 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
41 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
42 cryoglobulinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100778
43 multifocal epileptiform discharges 58 31 occasional (7.5%) Occasional (29-5%) HP:0010841
44 pedal edema 31 occasional (7.5%) HP:0010741
45 abnormal retinal vascular morphology 31 occasional (7.5%) HP:0008046
46 abnormality of the retinal vasculature 58 Occasional (29-5%)
47 edema of the lower limbs 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

45 (showing 2, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4
2 immune system MP:0005387 9.36 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 320, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3 Orange Approved Phase 3
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Chlorambucil Approved Phase 3 305-03-3 2708
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
8
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
9
Morphine Approved, Investigational Phase 3 57-27-2 5288826
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
13
Tazobactam Approved Phase 3 89786-04-9 123630
14
Piperacillin Approved Phase 3 66258-76-2 43672
15
Vancomycin Approved Phase 3 1404-90-6 441141 14969
16
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
17
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
18
Idelalisib Approved Phase 3 870281-82-6
19
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
20
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Anesthetics, Dissociative Phase 3
23 Antiemetics Phase 3
24 Gastrointestinal Agents Phase 3
25 Autonomic Agents Phase 3
26 Neurotransmitter Agents Phase 3
27 Hematinics Phase 3
28 Central Nervous System Depressants Phase 3
29 Tranquilizing Agents Phase 3
30 Psychotropic Drugs Phase 3
31 Adjuvants, Immunologic Phase 3
32 Antiprotozoal Agents Phase 3
33 Antiparasitic Agents Phase 3
34 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
35 Analgesics Phase 3
36 Liver Extracts Phase 3
37 Cola Phase 3
38 Anti-Anxiety Agents Phase 3
39 Antipsychotic Agents Phase 3
40 Analgesics, Opioid Phase 3
41 Serotonin Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Antipruritics Phase 3
44 Respiratory System Agents Phase 3
45 Narcotics Phase 3
46 Antitussive Agents Phase 3
47 Epoetin alfa Phase 3 113427-24-0
48 Anesthetics Phase 3
49 Anesthetics, General Phase 3
50 Adjuvants, Anesthesia Phase 3
51 Anesthetics, Intravenous Phase 3
52 Excitatory Amino Acid Antagonists Phase 3
53 Excitatory Amino Acids Phase 3
54 Piperacillin, Tazobactam Drug Combination Phase 3
55 ferric gluconate Phase 3
56 Ferric Compounds Phase 3
57 Iron Supplement Phase 3
58 Liposomal amphotericin B Phase 3
59 Bendamustine Hydrochloride Phase 3
60
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
61
Cysteamine Approved, Investigational Phase 1, Phase 2 60-23-1 6058
62
belimumab Approved Phase 2 356547-88-1 10451420 5957
63
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
64
Mesna Approved, Investigational Phase 2 3375-50-6 598
65
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
66
Methylcobalamin Approved, Investigational Phase 1, Phase 2 13422-55-4
67
Hydroxocobalamin Approved Phase 1, Phase 2 13422-51-0 11953898 15589840
68
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
69
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
70
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
71
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
72
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
73
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
74
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
75
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
76
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
77
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
78
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
79
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
80
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
81
Sulfamethazine Approved, Investigational, Vet_approved Phase 2 57-68-1 5327
82
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
83
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
84
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
85
Benzyl alcohol Approved Phase 2 100-51-6 244
86 Daratumumab Approved Phase 2 945721-28-8
87
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
88
nivolumab Approved Phase 1, Phase 2 946414-94-4
89
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
90
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
91 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
92
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
93
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
94
Acetaminophen Approved Phase 2 103-90-2 1983
95
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
96
Promethazine Approved, Investigational Phase 2 60-87-7 4927
97
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
98
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
99
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
100
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
101
Etoposide Approved Phase 2 33419-42-0 36462
102
Ixazomib Approved, Investigational Phase 2 1072833-77-2
103
Ichthammol Approved Phase 1, Phase 2 8029-68-3
104
Acyclovir Approved Phase 2 59277-89-3 2022